Second ESMO consensus conference on lung cancer: Pathology and molecular biomarkers for non-small-cell lung cancer

Keith M. Kerr; Lukas Bubendorf; Martin J. Edelman; Antonio Marchetti; Tony Mok; Silvia Novello; Ken O'Byrne; Rolf Stahel; Solange Peters; Enriqueta Felip; Benjamin Besse; Johan Vansteenkiste; Wilfried Eberhardt; Paul Baas; Martin Reck; Konstantinos Syrigos; Luis Paz-Ares; Egbert F. Smit; Peter Meldgaard; Alex Adjei; Marianne Nicolson; Lucio Crinò; Paul Van Schil; Suresh Senan; Corinne Faivre-Finn; Gaetano Rocco; Giulia Veronesi; Jean Yves Douillard; Eric Lim; Christophe Dooms; Walter Weder; Dirk de Ruysscher; Cecile Le Pechoux; Paul de Leyn; Virginie Westeel

doi:10.1093/annonc/mdu145

Second ESMO consensus conference on lung cancer: Pathology and molecular biomarkers for non-small-cell lung cancer

Keith M. Kerr, Lukas Bubendorf, Martin J. Edelman, Antonio Marchetti, Tony Mok, Silvia Novello, Ken O'Byrne, Rolf Stahel, Solange Peters, Enriqueta Felip, Benjamin Besse, Johan Vansteenkiste, Wilfried Eberhardt, Paul Baas, Martin Reck, Konstantinos Syrigos, Luis Paz-Ares, Egbert F. Smit, Peter Meldgaard, Alex AdjeiMarianne Nicolson, Lucio Crinò, Paul Van Schil, Suresh Senan, Corinne Faivre-Finn, Gaetano Rocco, Giulia Veronesi, Jean Yves Douillard, Eric Lim, Christophe Dooms, Walter Weder, Dirk de Ruysscher, Cecile Le Pechoux, Paul de Leyn, Virginie Westeel

Research output: Contribution to journal › Article › peer-review

Abstract

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with nonsmall- cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas. © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

Original language	English
Article number	mdu145
Pages (from-to)	1681-1690
Number of pages	9
Journal	Annals of Oncology
Volume	25
Issue number	9
DOIs	https://doi.org/10.1093/annonc/mdu145
Publication status	Published - 2014

Keywords

Consensus
ESMO
Molecular testing
Non-small-cell lung cancer
Pathology
Recommendations

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdu145

http://annonc.oxfordjournals.org/

Cite this

Kerr, K. M., Bubendorf, L., Edelman, M. J., Marchetti, A., Mok, T., Novello, S., O'Byrne, K., Stahel, R., Peters, S., Felip, E., Besse, B., Vansteenkiste, J., Eberhardt, W., Baas, P., Reck, M., Syrigos, K., Paz-Ares, L., Smit, E. F., Meldgaard, P., ... Westeel, V. (2014). Second ESMO consensus conference on lung cancer: Pathology and molecular biomarkers for non-small-cell lung cancer. Annals of Oncology, 25(9), 1681-1690. Article mdu145. https://doi.org/10.1093/annonc/mdu145

@article{ef8a438d1d354ed1878a462098682c9c,

title = "Second ESMO consensus conference on lung cancer: Pathology and molecular biomarkers for non-small-cell lung cancer",

abstract = "To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with nonsmall- cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas. {\textcopyright} The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.",

keywords = "Consensus, ESMO, Molecular testing, Non-small-cell lung cancer, Pathology, Recommendations",

author = "Kerr, {Keith M.} and Lukas Bubendorf and Edelman, {Martin J.} and Antonio Marchetti and Tony Mok and Silvia Novello and Ken O'Byrne and Rolf Stahel and Solange Peters and Enriqueta Felip and Benjamin Besse and Johan Vansteenkiste and Wilfried Eberhardt and Paul Baas and Martin Reck and Konstantinos Syrigos and Luis Paz-Ares and Smit, {Egbert F.} and Peter Meldgaard and Alex Adjei and Marianne Nicolson and Lucio Crin{\`o} and Schil, {Paul Van} and Suresh Senan and Corinne Faivre-Finn and Gaetano Rocco and Giulia Veronesi and Douillard, {Jean Yves} and Eric Lim and Christophe Dooms and Walter Weder and {de Ruysscher}, Dirk and {Le Pechoux}, Cecile and {de Leyn}, Paul and Virginie Westeel",

year = "2014",

doi = "10.1093/annonc/mdu145",

language = "English",

volume = "25",

pages = "1681--1690",

journal = "Annals of Oncology",

issn = "1569-8041",

publisher = "Oxford University Press",

number = "9",

}

Kerr, KM, Bubendorf, L, Edelman, MJ, Marchetti, A, Mok, T, Novello, S, O'Byrne, K, Stahel, R, Peters, S, Felip, E, Besse, B, Vansteenkiste, J, Eberhardt, W, Baas, P, Reck, M, Syrigos, K, Paz-Ares, L, Smit, EF, Meldgaard, P, Adjei, A, Nicolson, M, Crinò, L, Schil, PV, Senan, S, Faivre-Finn, C, Rocco, G, Veronesi, G, Douillard, JY, Lim, E, Dooms, C, Weder, W, de Ruysscher, D, Le Pechoux, C, de Leyn, P & Westeel, V 2014, 'Second ESMO consensus conference on lung cancer: Pathology and molecular biomarkers for non-small-cell lung cancer', Annals of Oncology, vol. 25, no. 9, mdu145, pp. 1681-1690. https://doi.org/10.1093/annonc/mdu145

TY - JOUR

T1 - Second ESMO consensus conference on lung cancer: Pathology and molecular biomarkers for non-small-cell lung cancer

AU - Kerr, Keith M.

AU - Bubendorf, Lukas

AU - Edelman, Martin J.

AU - Marchetti, Antonio

AU - Mok, Tony

AU - Novello, Silvia

AU - O'Byrne, Ken

AU - Stahel, Rolf

AU - Peters, Solange

AU - Felip, Enriqueta

AU - Besse, Benjamin

AU - Vansteenkiste, Johan

AU - Eberhardt, Wilfried

AU - Baas, Paul

AU - Reck, Martin

AU - Syrigos, Konstantinos

AU - Paz-Ares, Luis

AU - Smit, Egbert F.

AU - Meldgaard, Peter

AU - Adjei, Alex

AU - Nicolson, Marianne

AU - Crinò, Lucio

AU - Schil, Paul Van

AU - Senan, Suresh

AU - Faivre-Finn, Corinne

AU - Rocco, Gaetano

AU - Veronesi, Giulia

AU - Douillard, Jean Yves

AU - Lim, Eric

AU - Dooms, Christophe

AU - Weder, Walter

AU - de Ruysscher, Dirk

AU - Le Pechoux, Cecile

AU - de Leyn, Paul

AU - Westeel, Virginie

PY - 2014

Y1 - 2014

N2 - To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with nonsmall- cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas. © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

AB - To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with nonsmall- cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas. © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

KW - Consensus

KW - ESMO

KW - Molecular testing

KW - Non-small-cell lung cancer

KW - Pathology

KW - Recommendations

U2 - 10.1093/annonc/mdu145

DO - 10.1093/annonc/mdu145

M3 - Article

SN - 1569-8041

VL - 25

SP - 1681

EP - 1690

JO - Annals of Oncology

JF - Annals of Oncology

IS - 9

M1 - mdu145

ER -

Second ESMO consensus conference on lung cancer: Pathology and molecular biomarkers for non-small-cell lung cancer

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this